Slide 1: ASCO 2011 Analyst Briefing
ASCO 2011 Analyst Briefing June 6, 2011
Slide 2: Forward Looking Statements
Forward Looking Statements • Our discussions during this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. • The factors that could cause actual results to differ are discussed in Pfizer’s 2010 Annual Repor
Slide 3: Leadership in Oncology
Leadership in Oncology Mace Rothenberg, MD, Senior Vice President of Clinical Development and Medical Affairs
Slide 4: The Evolution of Pfizer Oncology: Delivering on the Promise of Innovation and R&D
The Evolution of Pfizer Oncology: Delivering on the Promise of Innovation and R&D 1st regulatory approval of Epirubicin in France 1982 Irinotecan launches for metastatic colorectal carcinoma that has recurred AND WE’RE 1996 or progressed after treatment with 5-FU chemotherapy GROWING FDA approves Ar
Slide 5: Right Target, Right Drug(s), Right Patient
Right Target, Right Drug(s), Right Patient 5
Slide 6: Driving Improved Drug Development and Commercial Advantage
Driving Improved Drug Development and Commercial Advantage Clinical Development Smaller Clinical Trials + Less Costly, Faster Trial Completion Bigger Treatment Effect Earlier Regulatory Submission Commercial Benefits + Earlier Launch More Effective in Selected Patient Segments Patients Treated More
Slide 7: Pfizer Oncology Data at ASCO 2011
Pfizer Oncology Data at ASCO 2011
Slide 8: Pfizer Data at ASCO
Pfizer Data at ASCO RCC LUNG HEMATOLOGY Crizotinib Inotuzumab Ozogamicin PF-00299804 Bosutinib Axitinib 8
Slide 9: Advanced RCC: A Patient Population with Continued Unmet Needs
Advanced RCC: A Patient Population with Continued Unmet Needs Despite recent advances in the treatment of advanced RCC, patients are still in need of additional therapeutic options Up to 30% of RCC patients present with metastatic disease worldwide; Approximately 1/3 experience a recurrence Globally
Slide 10: Axitinib is an Oral and Selective Inhibitor of VEGF Receptors 1, 2, 3
Axitinib is an Oral and Selective Inhibitor of VEGF Receptors 1, 2, 3 Axitinib’s structure-based drug design allows strategic optimization of critical binding elements AXITINIB CONHM e H N S N Potency, selectivity • Simultaneously blocks VEGF 1,2,3 receptors N Solubility, metabolic stability, • VEGF
Slide 11: Phase 3 AXIS Trial: Axitinib 1st to Demonstrate Efficacy vs. Targeted Agent
Phase 3 AXIS Trial: Axitinib 1st to Demonstrate Efficacy vs. Targeted Agent in Phase 3 PFS by Prior Regimen Prior Treatment Axitinib Sorafenib Progression-free Survival Regimen (n=361) (n=362) HR P value* (IRC Assessment) Cytokines (n=251) 12.1 6.5 0.464 <0.0001 IRC Investigator 12.0 8.3 0.636 0.005
Slide 12: Global Burden of Lung Cancer
Global Burden of Lung Cancer With about 85% of all lung cancers being classified as NSCLC • Beyond histology, some patients have combination of tumor-driving genetic mutations or alterations with distinct molecular characteristics – Such as EGFR and anaplastic lymphoma kinase (ALK) Approximately 40,
Slide 13: Using the Genetic Makeup of a Person's Tumor to Classify and Treat Lung Cancer
Using the Genetic Makeup of A Person’s Tumor to Classify and Treat Lung Cancer 1999 2011 Adenocarcinoma Adenocarcinoma Histology-driven selection Targeting oncogenic drivers K-ras EGFR B-raf Her2 PIK3CA ALK MET Unknown CRIZOTINIB – A Potential Scientific Breakthrough: Targeting the ALK fusion gene,
Slide 14: Rapid Timeline from Compound Identification, Target Discovery and Clinical Results
Rapid Timeline from Compound Identification, Target Discovery and Clinical Results Clinical Testing Discovery of First Clinical Phase 3 Lung ASCO plenary NEJM Pfizer submits Begins EML4-ALK Responses Cancer Trial of expanded publication of NDAs to Fusion Gene Observed in Initiated ALK+ cohort1 ALK+
Slide 15: Phase 2 Study of Crizotinib: 51% Overall Response Rate & PRO Benefits
In Phase 2 Study of Crizotinib, 51% Overall Response Rate & PRO Show Clinically Meaningful Benefits* 5 5 Mean change from baseline Mean change from baseline 0 0 Fatigue (QLQ-C30) Pain (QLQ- –5 –5 C30) –10 –10 * * * * * * * * * * –15 –15 * –20 –20 N 122 114 110 112 103 97 70 N 122 114 110 112 103 97
Slide 16: Burden of Hematologic Malignancies
Burden of Hematologic Malignancies Hematologic malignancies represent the 5th most commonly occurring cancers and the second leading cause of cancer death worldwide Despite availability of existing treatments for patients with chronic myeloid leukemia, which accounts for 15% of all leukemias worldwi
Slide 17: Inotuzumab Ozogamicin
Inotuzumab Ozogamicin CLINICAL TRIAL SNAPSHOT Linker PHASE 2 • Inotuzumab in indolent NHL refractory to or relapsed after rituximab and Cytotoxic Antibody chemotherapy or radioimmunotherapy Calicheamicin G544: • Inotuzumab + rituximab in diffuse large Humanized-IgG4 B-cell lymphoma eligible for auto
Slide 18: Bosutinib
Bosutinib • 2ND generation dual inhibitor of Abl and Src family kinases – Potent ATP-competitive inhibitor of Bcr-Abl oncogene – 200x more potent than Gleevec – Unlike competitors, minimally inhibits PDGR [should this be PDGFR?] and cKIT STUDY 200 – CP Ph+ CML previously treated with both imatinib a
Slide 19: Bosutinib: BELA (Study 3000)
Bosutinib BELA (STUDY 3000) – 18 Month Follow-up in newly diagnosed chronic phase Philadelphia chromosome (Ph+) CML • MMR rate remains numerically favorable for bosutinib compared to imatinib (at 18 months 46% vs 38%, by 18 months 55% vs. 45%) • Rate of transformation: no new events in bosutinib arm
Slide 20: Broad Portfolio Delivers Innovation
Broad Portfolio Delivers Innovation
Slide 21: Multiple Investigational Compounds Addressing Unique Pathways
Multiple Investigational Compounds Addressing Unique Pathways Irreversible pan HER Inhibitor SMO and PF-00299804 oral, once daily, pan-HER inhibitor Hedgehog Signaling Inhibitor Activin PF-04449913 Receptor- Like small molecule, oral inhibitor of smoothened Kinase -1 (ALK- (SMO) 1) Inhibitor PF-0344
Slide 22: PF-00299804: Small Molecule Inhibitor of HER (EGFR), HER-2 and HER-4
PF-00299804: Small Molecule Inhibitor of HER 1 (EGFR), HER-2 and HER-4 Tyrosine Kinase Irreversible Pan-HER Inhibition HER 1 In lung cancer, pan-HER inhibition may HER2 HER3 HER4 (EGFR) more comprehensively block HER signaling pathway than currently No kinase activity marketed HER1 (EGFR) inhibitors
Slide 23: CDK 4/6 Inhibitor
CDK 4/6 Inhibitor CDK 4/6 inhibition has demonstrated antitumor activity in human xenograft models •More than 90% of human tumors circumvent control mechanisms for progression from G1 to S phase Phase I/II Breast Cancer Trial Phase I/II Multiple Myeloma Trial Letrozole With or Without PD 0332991 for
Slide 24: Key Takeaways
Key Takeaways Pfizer Oncology is... 1 Delivering on the promise of Rapid discovery of the ALK target to clinical results for crizotinib for personalized medicine as a leader in patients with advanced ALK- Oncology positive NSCLC 2 Making steady progress in accelerating science in areas of unmet need
Slide 25: Q&A
Q&A
Slide 26: ASCO 2011 Analyst Briefing
ASCO 2011 Analyst Briefing June 6, 2011